Research Papers:
MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2062 views | HTML 2458 views | ?
Abstract
Jiahui Fan1, Huaping Li1, Xiang Nie1, Zhongwei Yin1, Yanru Zhao1, Chen Chen1, Dao Wen Wang1
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Correspondence to:
Chen Chen, email: [email protected]
Dao Wen Wang, email: [email protected]
Keywords: miR-30c-5p, NAFLD, hepatic steatosis, FASN, db/db
Received: November 11, 2016 Accepted: January 02, 2017 Published: January 09, 2017
ABSTRACT
Approximately 15–40% of the general adult population suffers from non-alcoholic fatty liver disease (NAFLD) worldwide. However, no drug is currently licensed for its treatment. In this study, we observed a significant reduction of miR-30c-5p in the liver of leptin receptor-deficient (db/db) mice. Remarkably, recombinant adeno-associated virus (rAAV)-mediated delivery of miR-30c-5p was sufficient to attenuate triglyceride accumulation and hepatic steatosis in db/db mice. Through computational prediction, KEGG analysis and Ago2 co-immunoprecipitation, we identified that miR-30c-5p directly targeted fatty acid synthase, a key enzyme in fatty acid biosynthesis. Moreover, down-regulation of FASN by siRNA attenuated some key features of NAFLD, including decreased triglyceride accumulate and lipid deposition. Our findings reveal a new role of miR-30c-5p in counterbalancing fatty acid biosynthesis, which is sufficient to attenuate triglyceride accumulation and hepatic steatosis in db/db mice.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14561